SAN DIEGO and VANCOUVER, British Columbia, Nov. 22, 2016 /PRNewswire/ -- Sophiris Bio
Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a
biopharmaceutical company developing topsalysin (PRX302) for the
treatment of urological diseases, today announced that Randall
E. Woods, president and chief executive officer, will present a
corporate overview at the 28th Annual Piper Jaffray Healthcare
Conference. The presentation is scheduled for Wednesday,
November 30, 2016 at 9:30 a.m. EST in New York
at the Lotte Palace Hotel.
The presentation will be webcast live and can be accessed
through the Investor Relations page at www.sophiris.com. A
replay of the presentation will be available on the Company's
website for 90 days.
About Sophiris
Sophiris Bio Inc. is a biopharmaceutical company developing
topsalysin, a clinical-stage, targeted therapy for the treatment of
urological diseases. Topsalysin has successfully completed a Phase
2a clinical trial for the treatment of localized low to
intermediate risk prostate cancer. Topsalysin has also successfully
completed a Phase 3 clinical study for the treatment of the
symptoms of benign prostatic hyperplasia (BPH), and is designed to
be as efficacious as pharmaceuticals, less invasive than the
surgical interventions, and without the sexual side effects seen
with existing treatments. For more information, please
visit www.sophiris.com.
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
Sophiris' current beliefs as well as assumptions made by and
information currently available to Sophiris and relate to, among
other things, anticipated financial performance, business
prospects, strategies, regulatory developments, market acceptance
and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by Sophiris in its
public securities filings; actual events may differ materially from
current expectations. Sophiris disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Company Contact:
Peter
Slover
Chief Financial Officer
(858) 777-1760
Corporate Communications and Investor Relations:
Michael
Moore
NATIONAL
Equicom
Investor
Relations
(858)
886-7813
mmoore@national.ca
|
Jason
Spark
Canale
Communications
Corporate
Communications and
IR
(619)
849-6005
jason@canalecomm.com
|
Logo - http://photos.prnewswire.com/prnh/20161121/441889LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-28th-annual-piper-jaffray-healthcare-conference-300366994.html
SOURCE Sophiris Bio Inc.